Nijmegen Bladder Cancer Study

Study Name: Nijmegen Bladder Cancer Study

Principal Investigators:
Prof. Dr. Lambertus (Bart) A. Kiemeney (RUNMC)
Dr. Katja K.H. Aben (IKO)
Dr. Sita H. Vermeulen (RUNMC)

Additional researchers:
Prof. Dr. J. Alfred (Fred) Witjes, RUNMC
Dr. Martin den Heijer, RUNMC
Dr. Dorine Swinkels, RUNMC
Dr. Barbara Franke, RUNMC

Institution/s:
Radboud University Nijmegen Medical Centre (RUNMC)
Nijmegen, the Netherlands
Comprehensive Cancer Centre East (IKO)
Nijmegen, the Netherlands

Institution/s address:
Radboud University Nijmegen Medical Centre (RUNMC)
Department of Epidemiology and Biostatistics (133)
Department of Urology (459)
P.O. Box 9101
NL-6500 HB Nijmegen, the Netherlands

Comprehensive Cancer Centre East (IKO)
P.O. Box 1281
NL-6501 BG Nijmegen, the Netherlands

Key References:
Kiemeney LA, Sulem P, Besenbacher S, et.al. A sequence variant at 4p16.3 confers susceptibility to urinary bladder cancer. Nat Genet 2010; 42(5): 415-9.
Kiemeney LA, Thorlacius S, Sulem P, et.al. Sequence variant on 8q24 confers susceptibility to urinary bladder cancer. Nat Genet 2008; 40(11): 1307-1312.

Study Design: Population-based case-control. Cases have been retrospectively and are prospectively being identified and recruited from the populationbased cancer registry of IKO

Matching factors:

Country: The Netherlands

ICD-0-3 morphology codes: 8000, 8020, 8041, 8045, 8070, 8071, 8120, 8130, 8140, 8246, 8480, 8481, 8490, 8560, 8700

Follow up of cases? Yes

Expected time of follow-up? Currently 1-15 years

	Cases	Controls
Years of enrollment	2007-2010 (years of diagnosis 1975-2009)	2002-2003
Source population	IKO Populationbased cancer registry, covering 8 hospitals and 1.3 million inhabitants	Nijmegen Municipal Population Administration covering 150,000 inhabitants
Response rate (enrolled/eligible)	62%	9,350 / 21,756 -> 43%
Total number enrolled	1,974	9,350
Subjects with DNA	1,914	6,468
Ethnic origin	>99% Caucasian	>99% Caucasian
Age: mean (range)	62.3 range (25-93)	54 (18 – 100)
Gender: % males	81.5%	46%

Questionnaire data	Cases	Controls
Demographics (age, sex, ethnicity, region, education etc..)	x	x
Active smoking	x	x
Passive smoking	-	-
Occupational exposures	x	x
Residential history	-	-
Water chlorination byproducts	-	-
Arsenic exposure	-	-
Other environmental exposures	-	-
Hair dye use	x	x
Drug use	x	x
Medical History	x	x
Family History	x	x
Quality of life	-	-
Diet/nutrition	x	x
Caffeine intake	-	x
Fluid intake	x	-
Urine pH measurements	-	-
Other information, please specify * incl. urinary tract infections treated with antibiotics, bladder stones, catheter, X-ray exposure abdomen/pelvis # exposure during conception / pregnancy first child, including cosmetic products, X-ray, anaesthetics, cytostatics, industrial cleaners, paint, pesticides.	physical activity, artificial sweeteners, urination frequency	physical activity

Biological Samples	Cases	Controls
Blood DNA	x	x
Buccal DNA	-	-
Serum/plasma	-	x
Cryopreserved whole blood / lymphocytes	-	-
Red blood cells	-	-
Urine samples	-	x
Toenail clippings	-	-
Others, please specify	-	-
Paraffin tissue blocks	x
Frozen tissue	-

Information at time of diagnosis	Cases
For Cases Only
Histological confirmation	x
Number of tumors	-
Tumor site	x
Tumor size	-
Tumor grade	x
Growth pattern	-
Treatment of primary tumor	x
Stage	x
Other information, please specify	-

Follow-up information	Cases
Treatment information	-
Tumor recurrence	x
Tumor progression	x
Survival	x
Histological confirmation	x
Number of tumors	x
Tumor site	x
Tumor size	x
Tumor grade	x
Growth pattern	x
Stage	x
Active smoking	x
Occupational exposures	-
Drug use	-
Medical History	x
Quality of life	-
Caffeine intake	-
Fluid intake	-
Other information , please specify	-